

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.**

**百奥赛图(北京)医药科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

### **POSITIVE PROFIT ALERT**

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company is pleased to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2024 and the information currently available to the Board, the revenue of the Group for the year ended December 31, 2024 is expected to be approximately RMB969.3 million to RMB989.3 million, as compared with the revenue for the year ended December 31, 2023 of approximately RMB716.9 million, representing a year-on-year increase of approximately 35.2% to 38.0%. The net profit of the Group for the year ended December 31, 2024 is expected to be approximately RMB20.0 million to RMB40.0 million, whereas the loss for the year ended December 31, 2023 was approximately RMB383.0 million. The research and development expenses of the Group for the year ended December 31, 2024 is expected to be approximately RMB311.6 million to RMB331.6 million, as compared with the research and development expenses for the year ended December 31, 2023 of approximately RMB474.4 million, representing a year-on-year decrease of approximately 30.1% to 34.3%.

The Board is of the view that the improvement in the results of the Company in 2024 is mainly due to the following factors:

1. The antibody discovery business was recognized by more overseas customers, and the number of external transfers of antibody molecules increased rapidly. Our sales revenue grew rapidly, and the gross profit margin maintained a relatively high level;
2. The gene editing animal model business continued to maintain rapid growth, especially the continuous development of overseas markets led to a further increase in the proportion of revenue contributed by overseas businesses, while maintaining a relatively high level of gross profit margin; and
3. The Group achieved remarkable results in strategic adjustment, with the R&D investment significantly decreasing as compared with the same period of last year, and the lean management achieved initial results. The Group focused on the direction of research and development, and its R&D activities concentrated to serve the medium-to-long-term development of its main business lines. The Group strived to improve operational efficiency and control costs and expenses.

The information contained in this announcement is based solely on the preliminary estimates made by the Board based on information currently available to the Group, including the unaudited management accounts of the Group in the 2024 financial year, and is subject to change. The information contained in this announcement is not based on any figures or data which have been audited or reviewed by the Company's auditors. Accordingly, the actual results of the Group may be different from what is disclosed in this announcement. Shareholders and potential investors are advised to read the annual results announcement of the Company for the year ended December 31, 2024 carefully, which is expected to be published by the end of March 2025.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**  
**Shen Yuelei**  
*Chairman of the Board, Chief Executive Officer  
and Executive Director*

Hong Kong, January 27, 2025

*As at the date of this announcement, the Board of the Company comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.*